Risk factors for statin‐associated rhabdomyolysis
Authors:
- Stephanie SchechSSStephanie Schech
- Susan E. AndradeSASusan E. Andrade
- K. Arnold ChanKCK. Arnold Chan
- Richard PlattRPRichard Platt
- 7 August 2006
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 16 (3) , 352-358
Abstract
Purpose: To identify and characterize risk factors for rhabdomyolysis in patients prescribed statin monotherapy or statin plus fibrate therapy.Methods: A nested case‐control study was conducted within a cohort of 252 460 new users of lipid‐lowering medications across 11 geographically dispersed U.S. health plans. Twenty‐one cases of rhabdomyolysis confirmed by medical record review were compared to 200 individually matched controls without rhabdomyolysis. A conditional logistic regression model was applied to evaluate the effects of age, gender, comorbidities, concurrent medication use, dosage, and duration of statin use on the development of rhabdomyolysis.Results: Statin users 65 years of age and older have four times the risk of hospitalization for rhabdomyolysis than those under age 65 (odds ratio (OR) = 4.36, 95% confidence interval (CI): 1.5,14.1). We also observed a joint effect of high statin dosage and renal disease (p = 0.022). When these two variables were added to the model with age, we obtained an OR of 5.73 for dosage (95%CI: 0.63, 52.6) and 6.26 for renal disease (95%CI: 0.46, 63.38). Although not statistically significant, we did observe a greater than twofold increase in risk for rhabdomyolysis among females (OR = 2.53, 95%CI: 0.91, 7.32).Conclusions: Findings of this study indicate that older age is a risk factor for rhabdomyolysis among statin users. Although the evidence is not as strong, high statin dosage, renal disease, and female gender may be additional risk factors. Patients at higher risk of developing rhabdomyolysis should be closely monitored for signs and symptoms of the disease. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 18 references indexed in Scilit:
- Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysisJournal of Clinical Epidemiology, 2005
- Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering DrugsJAMA, 2004
- Specificity and Sensitivity of Claims‐Based Algorithms for Identifying Members of Medicare+Choice Health Plans That Have Chronic Medical ConditionsHealth Services Research, 2004
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Statin-Associated MyopathyJAMA, 2003
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Rhabdomyolysis and HMG-CoA Reductase InhibitorsAnnals of Pharmacotherapy, 2001
- Efficacy and Safety of Cerivastatin 0.8 mg in Patients with Hypercholesterolaemia: The Pivotal Placebo-Controlled Clinical TrialJournal of International Medical Research, 2000
- Acute Rhabdomyolysis during Treatment with Ofloxacin--A Case ReportClinical Infectious Diseases, 1999
- Using Claims Data for Epidemiologic ResearchMedical Care, 1993